August 4th, 2021 | 12:21 CEST
Evotec, Barsele Minerals, Nikola - When will the starting signal follow?
Table of contents:
"[...] The transaction offers benefits to all parties: Shareholders now have three promising projects in their portfolio. [...]" Bradley Rourke, President, CEO and Director, Scottie Resources Corp.
Special situation in Northern Europe
An exciting opportunity is currently available in northern Sweden, about 500km from the capital Stockholm. Here lies the approximately 47,000-hectare Barsele project in the Fennoscandian Shield, which intersects the historically high-grade "gold line" and, from a geological perspective, represents two different mineral trends. To date, resources have been expanded from 1 million ounces to 2.5 million ounces. According to Barsele Minerals management, the project could eventually yield up to 5 million ounces of gold. In addition, there is the possibility of extracting other commodities such as silver, lead, zinc and nickel.
In addition to the exploration company Barsele Minerals, which owns 45%, the majority of 55% is currently owned by the gold producer Agnico Eagle. Agnico has also carried out exploration work over 160 km and over 400 drill holes in the past. The fact that Agnico will focus on developing new mining projects in North America in the future opens up a unique opportunity for the young company. A letter of intent was signed by Aug. 31 for Barsele to acquire the 55% of Agnico Eagle by paying USD 45 million to become the sole owner. Barsele Minerals will grant the other party 14.9% of its shares and 6 million warrants at the final closing. The project is to be financed by a convertible bond and a capital increase, which is also intended to strengthen the equity base of Barsele Minerals further.
A further 30,000 meters of drilling are now planned over the next two years. The target of the experienced management is then 3.5 million ounces. In the longer term, however, at least a doubling is expected internally. The reason is obvious. The Barsele project extends over a total of 8km. However, the resource estimate to date only covers about 3km of this section. In addition, the previous estimates are limited to a depth of 450m. However, deeper drilling has already identified further potential.
The Barsele Project is currently one of the most interesting mining projects on the market. Barsele Minerals, managed by the Belcarra Group, has many years of experience in project development. The project's development to the preliminary feasibility stage and the subsequent possible resale to larger producers promise enormous increases in the value of the shares.
You can read the full interview with Barsele Minerals CEO Gary Cope here
New blow for Nikola
The bad news continues at truck builder Nikola. Last week, the New York Attorney General's Office filed charges against founder and former CEO Trevor Milton. He resigned last September amid allegations of fraud, after which the stock exited trading with double-digit losses.
Now Nikola reported second-quarter numbers. Sales were not expected at the hybrid truck company. Earnings per share were negative USD 0.20, up from negative USD 0.16 in the same period last year. Although analyst firms were forecasting an even higher loss of USD 0.301, the stock lost more than 6% after the market opened at USD 10.40, near its low for the year at USD 9.65. Despite operational successes in recent weeks, an investment in Nikola resembles a gamble and is thus only suitable for hard-nosed investors.
Milestone payment in sight
In contrast, there is good news from Evotec. The research partnership with the pharmaceutical giant Bayer means that the M-DAX company can look forward to a milestone payment. Bayer announced that the primary efficacy endpoint was reached in a Phase IIb clinical trial with its development candidate Eliapixant for the treatment of chronic cough. The underlying compound is from Evotec.
According to company announcements, under the 2012 agreement, the next financial milestone payment would be triggered by the initiation of a Phase III clinical trial, as determined by Bayer. After the share successfully defended the support at EUR 34, the stock exited the trading session with a gain of almost 3%. In the long term, the news that the biotech company still intends to list its shares on the US technology exchange NASDAQ in 2021 should also be viewed positively.
In the long term, due to the current framework data such as national debt, low interest rates, and rising inflation, hardly anything passes an investment in gold. Barsele Minerals has the opportunity to create significant long-term value for its shareholders. The starting position of biotechnology Company Evotec is also positive. By contrast, Nikola is only something for extremely speculative investors.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.